Filing Details

Accession Number:
0001209191-18-024986
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-04-16 16:22:00
Reporting Period:
2018-04-12
Accepted Time:
2018-04-16 16:22:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
908259 Mateon Therapeutics Inc MATN Biological Products, (No Disgnostic Substances) (2836) 133679168
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1236260 M Matthew Loar C/O Mateon Therapeutics, Inc.
701 Gateway Blvd., Suite 210
South San Francisco CA 94080
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-04-12 250,000 $0.00 300,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock A Warrant (Right to Buy) Acquisiton 2018-04-12 125,000 $0.00 125,000 $0.40
Common Stock Common Stock B Warrant (Right to Buy) Acquisiton 2018-04-12 125,000 $0.00 125,000 $0.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
125,000 2018-04-12 2020-04-12 No 4 P Direct
125,000 No 4 P Direct
Footnotes
  1. The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share.
  2. The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date").
  3. The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years.